Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 5/20 | 0.44 |
| ▸ | PRCP | P42785 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSH | P09668 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31437204 | 0.96 | EPHA2 (0.48) | EPHA2OPRM1OPRK1CXCR4CTSL | |
| SCHEMBL31467758 | 0.95 | PRCP (0.46) | EPHA2PRCPKMT2AOPRM1OPRK1 | |
| SCHEMBL31437156 | 0.93 | PTPN1 (0.43) | EPHA2PRCPPTPN1KMT2ACXCR4 | |
| SCHEMBL31157628 | 0.89 | CTSL (0.47) | EPHA2CTSLCTSHCTSSCTSK | |
| SCHEMBL31437193 | 0.89 | PRCP (0.51) | PRCPKMT2A | |
| SCHEMBL31437163 | 0.88 | PRCP (0.44) | EPHA2PRCPKMT2ACXCR4 | |
| SCHEMBL31437197 | 0.88 | PRCP (0.47) | PRCPOPRM1OPRK1 | |
| SCHEMBL31437183 | 0.87 | PRCP (0.43) | EPHA2PRCPKMT2AOPRM1OPRK1 | |
| SCHEMBL31467771 | 0.86 | PRCP (0.43) | EPHA2PRCPOPRM1OPRK1 | |
| SCHEMBL31437208 | 0.84 | PRCP (0.45) | EPHA2PRCPOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025037993-A1 | DOSAGE FORM FOR PEPTIDE AGENTS | MAJEWSKI FILIP (PL) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025037992-A1 | NEW PEPTIDES AND USE THEREOF | MAJEWSKI FILIP (PL) | 2025-02-20 | — | — | WO | disclosed |